logo

CRVO

CervoMed·NASDAQ
--
--(--)
--
--(--)
3.61 / 10
Netural

Fundamental assessment is guarded, scoring 3.6/10. Key concerns include low net profit margin relative to total profit and suboptimal asset-to-market value, while revenue and profit metrics show some strength. Historical back-tests indicate limited upside potential, with one-month returns ranging from -0.30% to 11.69% across different factors.

Fundamental(3.61)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-3.81
Score2/3
Weight24.35%
1M Return11.69%
Inventory turnover ratio
Value47.85
Score3/3
Weight9.38%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight21.45%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight15.98%
1M Return7.79%
PB-ROE
Value1.25
Score0/3
Weight7.30%
1M Return3.56%
Current assets turnover ratio
Value0.11
Score1/3
Weight-0.81%
1M Return-0.48%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.36%
1M Return0.86%
Asset-MV
Value-0.50
Score0/3
Weight5.46%
1M Return2.94%
Cash-MV
Value-0.07
Score2/3
Weight16.00%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.47%
1M Return-0.30%
Is CRVO fundamentally strong?
  • CRVO scores 3.61/10 on fundamentals and holds a Fair valuation at present. Backed by its -57.90% ROE, -415.36% net margin, -1.92 P/E ratio, 1.89 P/B ratio, and -33.64% earnings growth, these metrics solidify its Netural investment rating.